Stocktoria
CONMED Corp CNMD
CONMED Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B | $862.5M | $955.1M | $859.6M | $796.4M | $763.5M |
| Gross profit | $750.5M | $733.0M | $676.2M | $571.2M | $568.0M | $460.3M | $524.7M | $469.1M | $431.0M | $408.3M |
| R&D expense | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M | $40.5M | $45.5M | $42.2M | $32.3M | $32.3M |
| SG&A expense | $592.0M | $478.3M | $503.0M | $454.0M | $414.8M | $373.8M | $400.1M | $355.6M | $351.8M | $338.4M |
| Operating income | $102.6M | $200.3M | $120.6M | $70.1M | $109.7M | $46.0M | $79.1M | $71.3M | $46.9M | $37.7M |
| Interest expense | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M | $44.1M | $42.7M | $20.7M | $18.2M | $15.4M |
| Income tax | $24.1M | $30.6M | $16.4M | $9.7M | $10.6M | -$7.9M | $2.6M | $9.8M | -$26.8M | $4.7M |
| Net income | $47.1M | $132.4M | $64.5M | -$80.6M | $62.5M | $9.5M | $28.6M | $40.9M | $55.5M | $14.7M |
| EPS (diluted) | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 | $0.32 | $0.97 | $1.41 | $1.97 | $0.52 |
| Operating cash flow | $170.7M | $167.0M | $125.3M | $33.4M | $111.8M | $64.5M | $95.1M | $74.7M | $65.6M | $39.9M |
| Free cash flow | $150.9M | $153.9M | $106.3M | $11.6M | $96.9M | $51.5M | $75.1M | $58.2M | $52.7M | $25.1M |
| Cash & equivalents | — | — | — | — | — | — | $25.9M | $17.5M | $32.6M | $27.4M |
| Inventory | $355.5M | $346.7M | $318.3M | $332.3M | $231.6M | $194.9M | $164.6M | $154.6M | $141.4M | $135.9M |
| Total assets | $2.3B | $2.3B | $2.3B | $2.3B | $1.8B | $1.8B | $1.8B | $1.4B | $1.4B | $1.3B |
| Total liabilities | $1.3B | $1.3B | $1.5B | $1.6B | $980.6M | $1.0B | $1.1B | $706.9M | $726.5M | $748.4M |
| Shareholders' equity | $1.0B | $962.7M | $834.2M | $745.5M | $785.4M | $709.0M | $710.5M | $662.3M | $631.4M | $580.6M |
Growth · year-over-year · Revenue CAGR 6.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +5.2% | +5.0% | +19.1% | +3.4% | +17.2% | -9.7% | +11.1% | +7.9% | +4.3% | +6.2% |
| Net income growth | -64.5% | +105.4% | — | -228.8% | +557.2% | -66.7% | -29.9% | -26.4% | +278.4% | -51.9% |
| EPS growth | -64.5% | +108.3% | — | -238.1% | +506.2% | -67.0% | -31.2% | -28.4% | +278.8% | -52.3% |
| Free cash flow growth | -2.0% | +44.7% | +818.1% | -88.1% | +88.1% | -31.4% | +29.0% | +10.4% | +109.8% | -30.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.